Slowly but surely, progress is being made in terms of getting improved IBS medicines to market. Lexicon Pharmaceuticals have announced that the FDA has granted "Fast Track" status to their potential IBS-D drug, LX1033. This status helps to move the FDA approval process along more quickly. LX1033 is an oral medication, designed to act locally in the GI tract. The medication is currently undergoing a Phase II clinical trial.
More on LX1033 from Dr. Bolen, Your IBS Guide
"Lexicon's Drug Candidate for Irritable Bowel Syndrome Receives Fast Track Status from the FDA" Lexicon Pharmaceuticals Website December 17, 2012
|Facebook | Twitter | Google+ | Newsletter Signup | Forum|